A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Administration of Multiple Ascending Doses for 8 Days in Healthy Male or Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 31 May 2018
At a glance
- Drugs AZD 5069 (Primary)
- Indications Asthma; Bronchiectasis; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 31 May 2018 Results summarizing the PK profile of AZD5069 from eight phase 1 studies (NCT00953888, NCT01051505, NCT01083238, NCT01100047, NCT01332903, NCT01480739, NCT01735240, NCT01989520; n=240) published in the Drugs in R and D
- 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual patient number (8) added as reported by ClinicalTrials.gov.